Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

#1811

Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).

Aim(s): Pooled data from 5 LAN studies and their extensions provided an overview of safety in NETs.

Materials and methods: Data were pooled from CLARINET (96-week DB + ≤6-year long-term open-label [LTOL] extension), ELECT (16-week DB + 3-week initial OL + ≥2-year LTOL extensions) and OL studies of CS symptom relief (6 months), self-administered LAN (7–8 months) and tumour-growth control (92 weeks). Diarrhoea and flushing were excluded for ELECT DB + initial OL phases as they were efficacy measures.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Phan A, Wolin E, Fisher G, Ruszniewski P, Pavel M,

Keywords: Lanreotide, safety,